Baseline sCD14 levels are significantly inversely correlated with OS in HIV-NHL patients, and dynamic reductions in sCD14 and LBP following R-EPOCH therapy may indicate a partial reversal of immune activation, providing additional prognostic information [60]. The gene discussed is LBP; the disease is non-Hodgkin lymphoma.